Astellas Pharma Inc (ALPMY)

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

The chart shows the growth of an initial investment of $10,000 in Astellas Pharma Inc, comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.

Astellas Pharma Inc (ALPMY) has returned 22.05% so far this year and 67.91% over the past 12 months. Over the last ten years, ALPMY has returned 3.20% per year, falling short of the S&P 500 Index benchmark, which averaged 12.16% annually.

Based on dividend-adjusted daily data since Dec 18, 2008, ALPMY's average daily return is +0.01%, while the average monthly return is +0.20%. At this rate, your investment would double in approximately 28.9 years.

Historically, 52% of months were positive and 48% were negative. The best month was Oct 2019 with a return of +21.1%, while the worst month was May 2013 at -77.8%. The longest winning streak lasted 6 consecutive months, and the longest losing streak was 8 months.

On a daily basis, ALPMY closed higher 49% of trading days. The best single day was Aug 7, 2023 with a return of +10.6%, while the worst single day was May 13, 2013 at -75.7%.

Astellas Pharma Inc has an annualized alpha of -2.69%, beta of 0.40, and R² of 0.05 versus S&P 500 Index. Calculated based on daily prices since December 19, 2008.

• This stock participated in 54.23% of S&P 500 Index downside but only 8.80% of its upside — more exposed to losses than it benefited from rallies.
• Beta of 0.40 may look defensive, but with R² of 0.05 this stock is largely uncorrelated with S&P 500 Index — low beta reflects independence, not downside protection. See the Volatility section for a true picture of this stock's risk.
• R² of 0.05 means this stock moves largely independently of S&P 500 Index — capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

ALPMY ranks 93 for risk / return — in the top 93% of stocks on our site. This means strong returns relative to risk — exactly what professional investors look for. Well-suited for investors who want to maximize return per unit of risk.

The table below present risk-adjusted performance metrics for Astellas Pharma Inc (ALPMY) and compare them to a chosen benchmark (S&P 500 Index).

Astellas Pharma Inc provided a 0.00% dividend yield over the last twelve months, with an annual payout of $0.00 per share.

The table displays the monthly dividend distributions for Astellas Pharma Inc. The dividends shown in the table have been adjusted to account for any splits that may have occurred.

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.

The table below displays the maximum drawdowns of the Astellas Pharma Inc. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Astellas Pharma Inc was 83.67%, occurring on Apr 15, 2024. The portfolio has not yet recovered.

The current Astellas Pharma Inc drawdown is 70.04%.

The chart below shows the rolling one-month volatility.

The chart below illustrates the trends in the financial health of Astellas Pharma Inc over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

The Valuation section provides an overview of how Astellas Pharma Inc is priced in the market compared to other companies in the Drug Manufacturers - General industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.